Pacific Biosciences Enables Sale of Up to $100 Million in Shares Through At-the-Market Program
Key Facts
Pacific Biosciences entered into an agreement with Allen & Company on November 10, 2026, to sell common shares for gross proceeds of up to $100 million under an at-the-market offering program, according to a company filing with the U.S. Securities and Exchange Commission. The program allows sales to be made from time to time but does not require the company to sell any shares, so the announced cap is neither realized proceeds nor a commitment to raise the full amount. The filing sets out a framework for raising capital through share sales, while leaving the timing and actual size of any sales unspecified. The company may suspend sales requests and offers, and either party may terminate the agreement with advance notice. Sales therefore remain subject to the company's decision and execution conditions, rather than an automatic obligation to issue shares up to the cap.
Under the agreement, Allen & Company is entitled to compensation of up to 3.0% of the gross proceeds from shares it sells. This cap applies to shares sold through the agent, so it does not represent a fee on the entire announced amount unless all shares are sold up to the cap. The agreement also allows termination with 10 days' notice, under the disclosed terms. These provisions give the company room to decide whether to use the program and when to suspend it, while the agent's compensation is tied to the volume of sales executed. The disclosed information does not specify the number of shares to be sold or their price.
The company said potential proceeds would be used for research and development and working capital. This places the financing in the context of supporting the company's activities and operating needs, without the filing specifying a numerical allocation among these uses. Liquidity features in the financing picture presented in the third-quarter results: cash, cash equivalents and investments totaled $199.4 million at the end of September 2026, compared with $298.7 million at the end of September 2025. That means the balance at the end of the third quarter was below its level a year earlier, while proceeds from the share program remain contingent on actual sales if the company decides to proceed. The program cap should not be equated with cash already available, as the filing did not establish that the company had sold shares under it.
The agreement follows the announcement of third-quarter results, with revenue of $40.6 million compared with $38.4 million in the corresponding quarter of 2025. The company reported a GAAP net loss of $37.8 million for the same period, compared with a loss of $38.0 million a year earlier. These figures provide background on the company's financial performance before the agreement, alongside the year-over-year decline in cash and investments. The filing on the sales agreement does not identify a causal link between the third-quarter results and the decision, but places the new program in the context of liquidity and financing reflected in the published data.
An issuance of additional shares could dilute existing shareholders' ownership stakes, the company disclosed. About 312.237 million common shares were outstanding on September 30, 2026, the figure recorded before the sales agreement entered into in November. This figure does not mean the program will add a specific number of shares; the actual number and sale price are unspecified, and no sales are guaranteed. The extent of any potential dilution therefore depends on how many shares the company may sell later. Available closing data do not establish that the agreement affected the share price during the announcement session.
The company's shares closed at $2.24 on November 10, 2026, compared with a close of $2.36 in the previous session, according to EL7 data. This places the closing price on the day the agreement was entered into, without establishing on its own that the share move resulted from the announcement. Reliable verification of the session's trading range was unavailable, so the story does not include the high and low prices. The comparison between the two closes describes the price move between sessions, rather than explaining it. The company's third-quarter results were announced on November 4.
Pacific Biosciences had forecast full-year 2026 revenue of between $155 million and $160 million, according to its third-quarter results announcement. That range remains company guidance for the fiscal year, while the agreement provides a potential financing channel rather than operating revenue. If the company sells shares through the program, proceeds and the number of shares will depend on sales executed, subject to agent compensation of up to 3.0%. Any potential dilution likewise depends on an actual issuance, not the cap alone. The agreement's terms allow the company to suspend offers or terminate the agreement with 10 days' notice.